October 31, 2016 06:05 AM EDT

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform

John Carroll

Editor & Founder

AstraZeneca’s influential R&D leader Mene Pangalos has blasted the UK government’s drug watchdog NICE for keeping the price of new drugs at low levels, saying …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development

As­traZeneca R&D leader Pan­ga­los warns of a post-Brex­it UK re­search re­treat with­out re­im­burse­ment re­form

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform